Nafamostat mesilate, a noncalcium compound, as an anticoagulant, induces calcium-dependent haemolysis when infused with packed erythrocytes

Transfusion Medicine

Volumn 22, Issue 3, 2012, Pages 186-191

  Fujita, H ^a   Sakuma, R ^a   Fujimoto, S ^a   Hazama, Y ^a   Ohtake, C ^a   Moriyama, A ^a   Kuhara, K ^a   Nishimura, S ^a  

^a TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

Author keywords

Calcium; Co infusion; Protease inhibitor

Indexed keywords

CALCIUM; CHELATING AGENT; CITRIC ACID; EDETIC ACID; GABEXATE MESILATE; HEMOGLOBIN; HEPARIN; LACTATE DEHYDROGENASE; NAFAMSTAT MESILATE; PHOSPHATIDYLSERINE;

ANTICOAGULATION; ARTICLE; DOSE RESPONSE; DRUG INFUSION; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE MEMBRANE; ERYTHROCYTE TRANSFUSION; EXTRACELLULAR CALCIUM; HEMOLYSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFUSION PUMP; PROTEIN EXPRESSION;

ANTICOAGULANTS; CALCIUM; CITRATES; CITRIC ACID; DRUG EVALUATION, PRECLINICAL; EDETIC ACID; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; FLOW CYTOMETRY; GABEXATE; GLUCOSE; GUANIDINES; HEMOGLOBINS; HEMOLYSIS; HUMANS; INFUSION PUMPS; INFUSIONS, INTRAVENOUS; L-LACTATE DEHYDROGENASE; MEMBRANE LIPIDS; PHOSPHATIDYLSERINES; SOLUTIONS;

EID: 84861198654     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/j.1365-3148.2012.01154.x     Document Type: Article

References (23)

1. BCSH. (1999) The administration of blood and blood components and the management of transfused patients. Transfusion Medicine, 9, 227-238.
2. Birch, C., Hogan, C. & Mahoney, G. (2001) Co-administration of drugs and blood products. Anaesthesia and Intensive Care, 29, 137-140.
3. Clausen, T. (1998) Clinical and therapeutic significance of the Na+, K+ pump. Clinical Science, 95, 3-17.
4. Fujii, S. & Hitomi, Y. (1981) New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochimica et Biophysica Acta, 661, 342-345.
5. Fujita, H., Sakuma, R., Tomiyama, J., Hamaki, T., Ohwada, A., Kurosawa, S. & Nishimura, S. (2011) Increased phosphatidylserine exposure on the erythrocyte membrane in patients with polycythaemia vera. British Journal of Haematololgy, 152, 238-240.
6. Giunta, C., Cavaletto, M., Pergola, L., Pessione, E. & Bracchino, P. (1992) Modulation of Na+/K+ pump in intact erythrocytes by cardioglycosides, steroid hormones and ouabain-like compounds. General Pharmacology, 23, 683-687.
7. Han, S.J., Kim, H.S., Kim, L.I., Whang, S.M., Hong, K.S., Lee, W.K. & Lee, S.H. (2011) Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. Journal of Korean Medical Science, 26, 945-950.
8. Hitomi, Y., Ikari, N. & Fujii, S. (1985) Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis, 15, 164-168.
9. Kotani, K., Ichiba, S., Andou, M., Sano, Y., Date, H., Tedoriya, T., Goto, K. & Shimizu, N. (2002) Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation. Journal of Thoracic and Cardiovascular Surgery, 124, 626-627.
10. Lang, K.S., Lang, P.A., Bauer, C., Duranton, C., Wieder, T., Huber, S.M. & Lang, F. (2005a) Mechanisms of suicidal erythrocyte death. Cell Physiology and Biochemistry, 15, 195-202.
11. Lang, P.A., Kempe, D.S., Myssina, S. et al. (2005b) PGE2 in the regulation of programmed erythrocyte death. Cell Death Differentiation, 12, 415-428.
12. Levac, B., Parlow, J.L., van Vlymen, J., James, P., Tuttle, A. & Shepherd, L. (2010) Ringer's lactate is compatible with saline-adenine-glucose-mannitol preserved packed red blood cells for rapid transfusion. Canadian Journal of Anesthesia, 57, 1071-1077.
13. Murdock, J., Watson, D., Doree, C.J., Blest, A., Roberts, M.M. & Brunskill, S.J. (2009) Drugs and blood transfusions: dogma- or evidence-based practice?. Transfusion Medicine, 19, 6-15.
14. Muto, S., Imai, M. & Asano, Y. (1994) Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct. British Journal of Pharmacology, 111, 173-178.
15. Ohtake, Y., Hirasawa, H., Sugai, T., Oda, S., Shiga, H., Matsuda, K. & Kitamura, N. (1991) Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contributions to Nephrology, 93, 215-217.
16. Ookawara, O., Tabei, K., Sakurai, T., Sakairi, Y., Furuya, H. & Asano, Y. (1996) Additional mechanisms of nafamostat mesilate-associated hyperkalaemia. European Journal of Clinical Pharmacology, 51, 149-151.
17. Ota, T., Okada, K., Kano, H. & Okita, Y. (2007) Cardiopulmonary bypass using nafamostat mesilate for patients with infective endocarditis and recent intracranial hemorrhage. Interactive CardioVascular and Thoracic Surgery, 6, 270-273.
18. Quan, G.B., Han, Y., Yang, C., Ho, W.B., Liu, A., Wang, J.X., Wang, Y. & Liu, M.X. (2008) Inhibition of high glucose-induced erythrocyte phosphatidylserine exposure by leupeptin and disaccharides. Cryobiology, 56, 53-61.
19. Ryden, S.E. & Oberman, H.A. (1975) Compatibility of common intravenous solution with CPD blood. Transfusion, 15, 250-255.
20. Shimokawa Miyama, T., Yoshioka, C., Okawa, T., Hiraoka, H., Itamoto, K., Mizuno, T. & Okuda, M. (2010) Journal of Veterinary Medical Science, 72, 363-367.
21. van den Bos, A., Wissink, W.M., Schattenberg, A.V.M.B., Werre, J.M. & de Pauw, B.E. (2003) Feasibility of a new in vitro approach to evaluate cellular damage following co-infusion of red blood cell concentrates and intravenous drug solution. Clinical Laboratory Haematology, 25, 173-178.
22. Wood, B.L., Gibson, D.F. & Tait, J.F. (1996) Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow cytometric measurement and clinical association. Blood, 88, 1873-1880.
23. Yousef, H.M., Padmore, R.F., Neurath, D.D. & Rock, G.A. (2006) The effect of patient-controlled analgesia on coadministered red blood cells. Transfusion, 46, 372-376.